Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
Patent, once issued, will provide composition of matter protection through 2040, with potential for additional term extension Next-generation anthracycline uses unique lipid-based delivery technology to bring hope to the estimated 58% of AML patients for whom no...
Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
- Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 60% (50% CR) in 2nd line AML subjects - AnnAraC has potential to fill significant unmet need and expected to increase 2nd line AML CRs more than double over existing 2nd line therapies - All 82...
Moleculin Reports Full Year 2023 Financial Results
- Year marked by growing body of positive Annamycin efficacy and safety clinical data expected to support advancement into a pivotal study for AML - Company to host conference call and webcast Monday, March 25th at 8:30 AM ET - Company to issue separate clinical trial...
Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast
In-depth discussion of stratification of Company's 2nd line data of Annamycin as a therapy for acute myeloid leukemia (AML) Guidance to be provided for clinical development strategy for advancement of Annamycin into potential AML pivotal registration study HOUSTON,...
Moleculin Announces Reverse Stock Split
HOUSTON, March 19, 2024 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced a 1-for-15...
Moleculin to Present at the 36th Annual ROTH Conference
Live webcast fireside chat on Monday, March 18th at 9:00 AM PT HOUSTON, March 12, 2024 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat...
Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3
- MB-106 AML Phase 1B/2 trial (MB-106) preliminary data readout: Reached 67% recruitment - MB-106 preliminary results: Intent to Treat CR rate of 40% plus a CR/ CRi rate of 47% (N=15); Dosed Per Protocol CR rate of 46% plus a CR/CRi rate of 54% (N=13) - First 1st line...
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
HOUSTON, Dec. 20, 2023 -- Moleculin Biotech, Inc. (NASDAQ: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it has entered into a...
Moleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL’s in Conjunction with ASH Annual Meeting
- CR rate of 36% in Intent to Treat or ITT (n=11) subjects with durability - CR rate of 44% in subjects treated with Annamycin (n=9) - Durability of CR's up to 8 months & climbing (no relapses to date) - Recruitment in MB-106 Phase 1B/2 clinical trial reaches 59%...
Moleculin Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months
- MB-106: CR rate of 38% (N=8) with durability up to 8 months - Builds on CRi rate of 60% in MB-105 monotherapy AML trial last cohort (N=5) - MB-107: Phase 1B median extended overall survival of 11 months for heavily pre-treated subjects (N=15) - MB-107 Phase 1B/2...